A mechanism-driven treatment for chronic lymphocytic leukemia?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

11 citing papers in PubMed.

1. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia.Blood · 2015
   Trial
2. Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?Mediterranean journal of hematology and infectious diseases · 2019
   Article
3. Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study.Haematologica · 2018
   Article
4. Ibrutinib in the real world patient: many lights and some shades.Haematologica · 2016
   Article
5. The 2016 revision of the World Health Organization classification of lymphoid neoplasms.Blood · 2016
   Review
6. Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.Mediterranean journal of hematology and infectious diseases · 2016
   Review
7. A Selective Novel Peroxisome Proliferator-Activated Receptor (PPAR)-α Antagonist Induces Apoptosis and Inhibits Proliferation of CLL Cells In Vitro and In Vivo.Molecular medicine (Cambridge, Mass.) · 2015
   Article
8. A role for oleoylethanolamide in chronic lymphocytic leukemia.Leukemia · 2014
   Article
9. Modern treatment in chronic lymphocytic leukemia: impact on survival and efficacy in high-risk subgroups.Cancer medicine · 2014
   Article
10. Ibrutinib for B cell malignancies.Experimental hematology & oncology · 2014
    Article
11. Multidisciplinary diagnostics of chronic lymphocytic leukemia: European Research Initiative on CLL - ERIC recommendations.Hematology, transfusion and cell therapy
    Review

Corrections and comments

• Comment on
  Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia.2013

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as